Quo vadis pharma industry?
The impact of VZP CR interventions on drug interaction prescrbing physicians in Kralovehradecky and Stredocesky regions
Biosimilars – specific features of the approval process in the European Union
First biosimilar monoclonal antibody introduced to clinical praxis: infliximab
Pharmaco-economics of biological treatment; focus on biosimilars
Effect of the infusion system on the quality of parenteral treatment
Steroid resistant asthma: classification, definition and molecular mechanisms